Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donna Ryan

Internal Medicine Baton Rouge, LA Medical Doctor

NPI 1801197363 CMS profile 869765

6400 Perkins Rd, Baton Rouge, LA 70808

Open in the dashboard

General payments

$991,214

789 records reported · program years 2019–2025

Research payments

$99,637

Paid to them · 48 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Donna Ryan of Baton Rouge, LA is reported in the CMS Open Payments database as having received $991,214 across 789 general payments and $99,637 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $248,368 224
2025 Research $11,029 2
2024 General $265,505 238
2023 General $60,407 39
2023 Research $50,470 28
2022 General $113,383 73
2022 Research $28,958 12
2021 General $92,517 80
2021 Research $3,570 2
2020 General $33,281 20
2020 Research $5,610 4
2019 General $177,753 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donna Ryan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Donna Ryan were reported at $248,368. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Donna Ryan Internal Medicine median Middle half National median
2019 $177,753 $159 $48–$570 $163
2020 $33,281 $119 $33–$402 $114
2021 $92,517 $135 $37–$521 $132
2022 $113,383 $141 $42–$496 $149
2023 $60,407 $149 $45–$519 $160
2024 $265,505 $154 $47–$537 $164
2025 $248,368 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $431,242 377 payments
  2. Lilly USA, LLC $173,631 152 payments
  3. Novo Nordisk AS $101,084 39 payments
  4. Eli Lilly and Company $78,664 65 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $63,538 53 payments
  6. Bausch Health US, LLC $28,934 3 payments
  7. Amgen Inc. $26,852 14 payments
  8. Regeneron Pharmaceuticals, Inc. $21,535 33 payments
  9. Sanofi-Aventis U.S. LLC $21,222 6 payments
  10. Currax Pharmaceuticals LLC $17,364 16 payments
  11. Other $27,150 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $411,095 123 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $390,094 136 payments
  3. Travel and Lodging $162,331 323 payments
  4. Food and Beverage $16,642 201 payments
  5. Grant $5,750 2 payments
  6. Honoraria $5,244 3 payments
  7. Education $59 1 payment
Products named General payments · program years 2019–2025
  1. Saxenda $161,798 142 payments
  2. ZEPBOUND $154,448 132 payments
  3. Wegovy $146,447 131 payments
  4. CONTRAVE Nutrition and Weight Loss $28,934 3 payments
  5. NO PRODUCT DISCUSSED $21,222 6 payments
  6. Ozempic $10,793 6 payments
  7. CONTRAVE Obesity $9,002 7 payments
  8. CONTRAVE Obesity $8,362 9 payments
  9. MOUNJARO $1,418 23 payments
  10. Da Vinci Surgical System $500 1 payment
  11. Other $548 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novo Nordisk AS $88,608 46 payments
  2. Amgen Inc. $11,029 2 payments

Records

837 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record